To the Editor On behalf of our coauthors, we write to report serious errors in our article, “Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study,” published online on September 27, 2018, and in the January 2019 issue of JAMA Oncology.1
This article reports a study that compared the risk of hepatocellular carcinoma (HCC) and mortality or liver transplant in patients with chronic hepatitis B infection who were treated with entecavir or tenofovir. The study evaluated a Korean nationwide population-based cohort of 24 156 patients who were treatment-naive adults and a validation cohort of 2701 hospital patients who had been treated with entecavir or tenofovir. The nationwide cohort data were retrieved from January 1, 2010, to December 31, 2016, and the hospital cohort data were gathered from January 1, 2010, to October 31, 2017. We concluded that tenofovir treatment was associated with a significantly lower risk of HCC and mortality or transplant compared with entecavir treatment.
Lim Y, Ko MJ. Notice of Retraction and Replacement. Choi et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019;5(1):30-36. JAMA Oncol. 2019;5(6):913–914. doi:10.1001/jamaoncol.2019.0576
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: